{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:50:11Z","timestamp":1787071811035,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Aims:<\/jats:title>\n                    <jats:p>The prognosis for acute myeloid leukemia (AML) in adults is poor. The epidemiologic profile of patients varies substantially across geographic locales, as do the cytogenetic abnormalities and FAB subtype of AML. Kashmiris are a genetically conserved population. In this study, we are investigating clinical and laboratory factors and outcomes to establish treatment protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>This was a prospective study with clinical profiles and laboratory parameters of 100 case records. The primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and induction outcomes at our centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Median age was 50 years. The most common FAB subtype observed was AML M2. Pallor was observed in all patients as a clinical sign, while splenomegaly was noted in 41%, hepatomegaly in 23%, lymphadenopathy in 7%, and extramedullary disease in 6%. The ELN risk stratification for patients who have received 3 + 7 demonstrated a significant influence on complete remission rates (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Survival correlated significantly with risk stratification (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.048), Eastern Cooperative Oncology Group score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041). Median overall survival was 13.7 months, with 52% all-cause mortality.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_964_25","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:44Z","timestamp":1765814564000},"page":"S3605-S3611","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Spectrum of Acute Myeloid Leukemia and Treatment Outcomes in Kashmiri Population: A Prospective Study"],"prefix":"10.4103","volume":"17","author":[{"given":"Afaq Ahmad","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad Ahmed","family":"Geelani","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Govind","family":"Rathod","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, AIIMS, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reashma","family":"Roshan","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Chozakade","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid Rasool","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshan","family":"Atta","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, SKIMS, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"R1-20260217","first-page":"379","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"R2-20260217","first-page":"7","article-title":"Cancer Statistics,","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R3-20260217","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype:Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"R4-20260217","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type:A report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"R5-20260217","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017:Estimates based on the global burden of disease study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R7-20260217","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41408-017-0011-1","article-title":"Improved outcome for AML patients over the years 2000-2014","volume":"7","author":"Bertoli","year":"2017","journal-title":"Blood Cancer J"},{"key":"R8-20260217","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12288-018-1051-9","article-title":"Clinical profile and short term outcome of adult patients with acute myeloid leukemia","volume":"35","author":"Jacob","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R9-20260217","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ajco.12333","article-title":"Long-term outcomes for patients with acute myeloid leukemia:A single-center experience from AIIMS, India","volume":"11","author":"Bahl","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"issue":"(14_suppl)","key":"R10-20260217","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1200\/jco.2004.22.90140.6711","article-title":"Acute myeloid leukemia (AML):A study of 516 patients","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"R11-20260217","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/jcrt.JCRT_1162_16","article-title":"Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia","volume":"16","author":"Namratha Udupa","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R12-20260217","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.4103\/ijmpo.ijmpo_175_17","article-title":"Clinical profile of acute myeloid leukemia in North India and utility of nontransplant measures in its management","volume":"40","author":"Shoket","year":"2019","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R13-20260217","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0019-509X.13053","article-title":"Haematologic and immunophenotypic profile of acute myeloid leukemia:An experience of Tata Memorial Hospital","volume":"40","author":"Ghosh","year":"2003","journal-title":"Indian J Cancer"},{"key":"R14-20260217","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia:Challenges and real world data from India","volume":"170","author":"Philip","year":"2015","journal-title":"Br J Haematol"},{"key":"R15-20260217","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia:2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"R16-20260217","first-page":"12","article-title":"Outcome of acute myeloid leukaemia in adults:A retrospective analysis","volume":"18","author":"Saikia","year":"2005","journal-title":"Natl Med J India"},{"key":"R17-20260217","first-page":"84","article-title":"Clinico-hematological profile of acute leukemia cases in Bihar:A multiparameter study in a tertiary-care hospital","volume":"15","author":"Shuchismita","year":"2022","journal-title":"J Lab Physicians"},{"key":"R18-20260217","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13039-022-00621-1","article-title":"Cytogenetic profile of adult acute myeloid leukemia in Egypt:A single-center experience","volume":"15","author":"Elnaggar","year":"2022","journal-title":"Mol Cytogenet"},{"key":"R19-20260217","first-page":"1837","article-title":"Clinical presentation of acute myeloid leukaemia-a decade-long institutional follow-up","volume":"67","author":"Kulsoom","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"R20-20260217","doi-asserted-by":"crossref","first-page":"5","DOI":"10.31557\/apjcb.2021.6.1.5-13","article-title":"Characteristics and survival of 927 moroccan adults with acute myeloid leukemia monocentric experience","volume":"6","author":"Kaltoum","year":"2021","journal-title":"Asian Pac J Cancer Biol"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_964_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:56:43Z","timestamp":1787068603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_964_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"journal-issue":{"issue":"Suppl 5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_964_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}